Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,206,857 papers from all fields of science
Search
Sign In
Create Free Account
NK 121
Known as:
NK-121
, NK121
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Broader (2)
Antineoplastic Agents
Carboplatin
CI 973
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Heat enhances the cytotoxicity ofcis-diamminedichloroplatinum(II) and its analoguescis-1,1-cyclobutane-dicarboxylato(2R)-2-methyl-1,4-butanediammineplatinum(II) andcis-diammine(glycolato)platinum in…
I. Takahashi
,
Y. Maehara
,
H. Kusumoto
,
S. Kohnoe
,
K. Sugimachi
Cancer Chemotherapy and Pharmacology
2004
Corpus ID: 24417130
Abstractcis-1,1-Cyclobutanedicarboxylato(2R)-2-methyl-1,4-butanediammineplatinum(II) (NK121) andcis-diammine(glycolato)platinum…
Expand
1996
1996
Interaction of cis-diamminedichloro-platinum(II) and its analogues cis-1,1- cyclobutanedicarboxylato(2R)-2-methyl-1,4-butanediammineplatinum(II) and cis-diammine(glycolato)platinum with hyperthermia…
Ikuo Takahashi
,
Yoshihiko Maehara
,
+4 authors
K. Sugimachi
Oncology
1996
Corpus ID: 46766170
The interaction of cis-1,1-cyclobutanedicarboxylato(2R)-2-methyl-1,4- butanediammineplatinum(II) (NK121) and cis-diammine…
Expand
1994
1994
Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
W. Elliott
,
B. J. Roberts
,
C. Howard
,
W. Leopold
Cancer Research
1994
Corpus ID: 11319158
[SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4- butane-diamine-N,N')platinum (CI-973) is a cisplatin analogue that…
Expand
1993
1993
Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines.
H. Nguyen
,
B. Sevin
,
+5 authors
M. Penalver
Cancer Investigation
1993
Corpus ID: 25932569
Cisplatin continues to be one of the most commonly used cytotoxic agent. Problems of drug resistance and nephrotoxicity have…
Expand
1993
1993
Hyperthermic enhancement of cell killing by five platinum complexes in human malignant melanoma cells grown as monolayer cultures and multicellular spheroids.
N. Kubota
,
M. Kakehi
,
T. Inada
International Journal of Radiation Oncology…
1993
Corpus ID: 21553220
1993
1993
Comparison of cytotoxicity and cell kinetic perturbations of 5 platinum compounds in gynecologic cancer cell-lines.
H. Nguyen
,
B. Sevin
,
+4 authors
K. Ochiai
International Journal of Oncology
1993
Corpus ID: 24767204
New platinum derivatives were synthesized to overcome problems of cisplatin resistance and nephrotoxicity. Five platinum…
Expand
Review
1993
Review
1993
[Cisplatinum compounds].
K. Ota
Gan to kagaku ryoho. Cancer & chemotherapy
1993
Corpus ID: 25532143
New cisplatinum derivatives of 254-S, DWA2114R and NK121 developed in Japan were reviewed. These three compounds have less…
Expand
1992
1992
Optimal administration schedules of the newly synthesized platinum analog nk121 and bleomycin analog nk313 in nude mice with squamous cell carcinoma
H. Kanazawa
,
Hideki Yokoe
,
Kikuo Takahashi
,
Ken-ichi Sato
Head and Neck
1992
Corpus ID: 21858368
To determine the optimal administration schedules of the newly synthesized, less nephrotoxic platinum analog NK121 and less…
Expand
1991
1991
Clinical Studies with Cisplatin Analogues, 254-S, DWA2114R and NK121
H. Majima
1991
Corpus ID: 74259930
Development of CDDP analogues in Japan has been concerned with second generation analogues, especially which need no hydration or…
Expand
1991
1991
[The characteristics of nasopharyngeal carcinoma cell strain against chemotherapeutic agents and cytokines].
M. Tsukuda
,
A. Kubota
,
M. Kaneko
,
T. Yoshida
,
S. Sawaki
Nihon Jibiinkoka Gakkai kaiho
1991
Corpus ID: 24371225
The closed relationship between nasopharyngeal carcinoma (NPC) and Epstein-Barr virus (EBV) has been pointed out. However, it…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE